Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes.

Publication Year: 2024

DOI:
10.2337/dc23-1750

PMCID:
PMC10834389

PMID:
38117469

Journal Information

Full Title: Diabetes Care

Abbreviation: Diabetes Care

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Duality of Interest. M.J.H. is a member of the scientific advisory board for SAb Biotherapeutics, a company developing a humanized version of ATG and seeking to eliminate SS, and has been a consultant for Sanofi. M.A.A. holds a patent for combination therapies with ATG. No other potential conflicts of interest relevant to this article were reported."

Evidence found in paper:

"This work was supported by the National Institutes of Health, National Institute of Allergy and Infectious Diseases (P01 AI042288)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025